Eledon Pharmaceuticals, Inc. (ELDN)
$2.34-4.10%Close
SELLCRISIS · day 32
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $181M
- Beta
- 0.85
- P/E (TTM)
- -2.36
- Short % float
- 14.41%
- Days to cover
- 8.8
- SI change
- -5.0%
- 1W
- -4.49%
- 1M
- -15.52%
- vs SPY 1W
- -4.35%
- vs SPY 1M
- -18.03%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 14
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-81.9%
REV YoY-
ROE-136.4%
EPS YoY-
ROA-78.2%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-2.36
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B3.69
P/FCF-
EV/EBITDA-2.15
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.65
ALTMAN Z-
CURR RATIO7.90
ND/EBITDA-
BETA0.85
Company news
FAQ
- What is LOPJLB’s current signal on ELDN?
- LOPJLB’s latest quantitative signal on Eledon Pharmaceuticals, Inc. (ELDN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ELDN in?
- Eledon Pharmaceuticals, Inc. (ELDN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Eledon Pharmaceuticals, Inc. (ELDN) do?
- Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protei…